Overview

A Multicenter, Randomized, Parallel, Two-Period, Non-Inferiority Study of EurofarmavsAlenia in Asthma and COPD Treatment

Status:
Not yet recruiting

Trial end date:
2022-12-30

Target enrollment:

Participant gender:

Summary

A phase III study, multicenter, randomized, parallel, open, two-period, comparative non-inferiority of Eurofarma versus Alenia® in the treatment of moderate to severe persistent asthma with and without obstructive pulmonary disease (COPD)

Phase:

Phase 3

Details

Lead Sponsor:

Eurofarma Laboratorios S.A.

Treatments:

Budesonide
Formoterol Fumarate